{"title":"Application of the CARE guideline as reporting standard in the Women’s Health Investigation","authors":"","doi":"10.21037/whi.2019.10.01","DOIUrl":"https://doi.org/10.21037/whi.2019.10.01","url":null,"abstract":"","PeriodicalId":125517,"journal":{"name":"Women’s Health Investigation","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114751486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A milestone in oncology has been reached in recent years with the advent of immune checkpoint inhibitors (ICIs) which target programmed cell death protein 1 (PD-1) or its ligand, PD-L1, and cytotoxic T-lymphocyte-associated protein 4 (CTLA4). ICIs were first approved by the Food and Drug Administration (FDA) for melanoma in 2011 and subsequently in several other tumor types. In contrast to more immunogenic solid tumor types, breast cancer (BC) is typically not characterized by a high tumor mutation burden which is known as one of the predictive biomarkers of response to ICI (well described in melanoma and lung cancer), and so it has been considered potentially less immunogenic.
{"title":"Immune checkpoint inhibitors: a potential treatment breakthrough for metastatic triple-negative breast cancer?","authors":"E. Pons-Tostivint, J. Delord, F. Dalenc","doi":"10.21037/WHI.2019.03.01","DOIUrl":"https://doi.org/10.21037/WHI.2019.03.01","url":null,"abstract":"A milestone in oncology has been reached in recent years with the advent of immune checkpoint inhibitors (ICIs) which target programmed cell death protein 1 (PD-1) or its ligand, PD-L1, and cytotoxic T-lymphocyte-associated protein 4 (CTLA4). ICIs were first approved by the Food and Drug Administration (FDA) for melanoma in 2011 and subsequently in several other tumor types. In contrast to more immunogenic solid tumor types, breast cancer (BC) is typically not characterized by a high tumor mutation burden which is known as one of the predictive biomarkers of response to ICI (well described in melanoma and lung cancer), and so it has been considered potentially less immunogenic.","PeriodicalId":125517,"journal":{"name":"Women’s Health Investigation","volume":"1605 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127449340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gestational weight gain is a modifiable risk factor that impacts both short and long term maternal and child health (1). In 2009, the Institute of Medicine (IOM, now the National Academy of Medicine) published guidelines, “Weight Gain in Pregnancy, Reexamining the Guidelines”, recommending pregnancy weight gain goals stratified based on prepregnancy BMI (2). Achieving these goals in the United States has been difficult: in 2012–2013, only 32.1% of parturients met the recommended gestational weight gain target (3). Nonetheless, there is evidence supporting the use of dietary and lifestyle modifications to improve both maternal weight gain and obstetric outcomes (4,5).
{"title":"Gestational weight gain and pregnancy outcomes: where does delivery timing fit in?","authors":"Joseph S. Fixler, E. Defranco","doi":"10.21037/WHI.2019.01.01","DOIUrl":"https://doi.org/10.21037/WHI.2019.01.01","url":null,"abstract":"Gestational weight gain is a modifiable risk factor that impacts both short and long term maternal and child health (1). In 2009, the Institute of Medicine (IOM, now the National Academy of Medicine) published guidelines, “Weight Gain in Pregnancy, Reexamining the Guidelines”, recommending pregnancy weight gain goals stratified based on prepregnancy BMI (2). Achieving these goals in the United States has been difficult: in 2012–2013, only 32.1% of parturients met the recommended gestational weight gain target (3). Nonetheless, there is evidence supporting the use of dietary and lifestyle modifications to improve both maternal weight gain and obstetric outcomes (4,5).","PeriodicalId":125517,"journal":{"name":"Women’s Health Investigation","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129785473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Who benefits from immunotherapy? What constitutes a breakthrough? Where do the blockbuster pharmaceutical come from? When are clinical and scientific dreams realized? Why does getting a drug to market require such a huge, long and costly investment? How do we pick the winners?
{"title":"Immunotherapy in cervical cancer: historic breakthroughs beating checkpoints","authors":"R. Penson","doi":"10.21037/whi.2018.11.01","DOIUrl":"https://doi.org/10.21037/whi.2018.11.01","url":null,"abstract":"Who benefits from immunotherapy? What constitutes a breakthrough? Where do the blockbuster pharmaceutical come from? When are clinical and scientific dreams realized? Why does getting a drug to market require such a huge, long and costly investment? How do we pick the winners?","PeriodicalId":125517,"journal":{"name":"Women’s Health Investigation","volume":"40 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124705163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：